Summary of Xtant Medical Conference Call Company Overview - **Company Name**: Xtant Medical (NYSEAM:XTNT) - **Industry**: Medical Technology, specifically focusing on regenerative products for orthopedic and spine procedures - **Core Focus**: Design, manufacturing, and commercialization of regenerative biologics and spinal implant systems [2][3] Key Points and Arguments Market Opportunity - The market opportunity in the orthobiologic space is significant, with a domestic market size of approximately **$11.5 billion** and the orthobiologic segment addressing about **$3 billion** of a total **$3.9 billion** [6][7] - Xtant Medical has over **450 Integrated Delivery Network (IDN)** agreements and **500 independent agents**, indicating a strong commercial reach [4] Financial Performance - The company reported a **19% year-over-year growth** in profitability [4] - Following the divestiture of the Coflex and Paradigm OUS businesses, Xtant Medical's cash position improved to over **$25 million**, while long-term debt was reduced to approximately **$11 million**, effectively halving it [5][22] - The company has achieved a **CAGR of 13.8%** since 2021, indicating strong organic growth [8] Product Innovation and Diversification - Xtant Medical has successfully integrated its manufacturing processes, allowing for better supply chain control and improved margins [3] - The company has expanded its product offerings significantly, introducing new categories such as amnion and growth factor product lines, and enhancing its demineralized bone matrix (DBM) products [11][12] - The introduction of the **Trivium product line** is expected to command a higher price point, with typical DBM products priced at **$90 to $100 per cc**, while Trivium products are expected to exceed **$250 per cc** [15] Strategic Focus Areas - The company is focusing on biologics as its core competency, with a shift in revenue sources from over **90%** from spine-related products to the high **60%** range [9] - Xtant Medical is also exploring opportunities in chronic wound care and surgical repair, leveraging its existing tissue bank capabilities [16][20] Operational Efficiency - The company emphasizes controlling operating expenses and has increased its distributor network to **600**, enhancing its market penetration [18] - The focus is on maximizing profitability from existing customers rather than acquiring new ones, as existing customers yield higher gross profit [19] Future Outlook - Xtant Medical is optimistic about its growth trajectory and believes it represents a compelling investment opportunity, despite past stock performance issues attributed to previous ownership structures [25][40] - The company is actively working on expanding its product lines and market reach, particularly in the soft tissue repair segment [46] Additional Important Information - The divestiture of the Coflex product line has allowed the company to refocus its resources and improve operational efficiency [23] - The management expressed confidence in the company's financial health and future growth potential, indicating that the stock price does not currently reflect the underlying business value [25][40]

Core Viewpoint - Xtant Medical has finalized transactions with Companion Spine, receiving a total of $10.7 million, which completes the sale of its Coflex® assets and Paradigm OUS businesses for an aggregate price of $21.4 million [1] Financial Summary - The recent payment of $10.7 million includes $8.2 million for the satisfaction of an unsecured promissory note and $2.2 million for working capital and other purchase price adjustments [1] - The total purchase price for the divestitures amounts to $21.4 million [1] Strategic Focus - The completion of these transactions allows Xtant Medical to concentrate on its higher-margin biologics business while placing its assets with a recognized leader in the neuro-musculoskeletal space [1] - The additional funds from the transaction will enable the company to reduce long-term debt and enhance cash liquidity [1] Company Overview - Xtant Medical Holdings, Inc. is a global medical technology company focused on surgical solutions for spinal and orthopedic conditions, emphasizing the design, development, and commercialization of orthobiologics [1]

Core Viewpoint - Xtant Medical Holdings, Inc. will participate in the Canaccord Genuity 2026 Musculoskeletal Conference, highlighting its focus on surgical solutions for spinal, orthopedic, and wound care disorders [1] Group 1: Company Participation - Xtant Medical's CEO, CFO, and COO will attend the conference on March 2, 2026, in New Orleans and virtually [1] - A webcast of the company's presentation will be available starting February 2, 2026, at 2:00 P.M. (ET) [1] - The management team will be available for virtual one-on-one meetings on the same day, with interested investors encouraged to contact their Canaccord Genuity representative [1] Group 2: Company Overview - Xtant Medical is a global medical technology company focused on surgical solutions, particularly in spinal, orthopedic, and wound care markets [1] - The company's mission emphasizes honoring the gift of donation to enhance patients' quality of life [1] - Xtant Medical is dedicated to the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems [1]

Core Viewpoint - Xtant Medical Holdings, Inc. has launched its next-generation synthetic bone graft, nanOss Strata, aimed at improving surgical outcomes for spinal and orthopedic conditions [1][4]. Product Details - nanOss Strata is made from hydroxycarbonapatite (HCA), which has higher solubility than traditional hydroxyapatite (HA), enhancing bioactivity and integration with surrounding bone tissue [2]. - The product features a nanocrystalline structure that mimics human bone, increasing surface area for better osteoconductivity and cellular activity stimulation post-implantation [2]. - Strata is available in two forms: compression-resistant preformed strips and prehydrated moldable grafts, both of which are sterile and absorb biologic fluids quickly [3]. Company Commitment - The CEO of Xtant Medical emphasized the company's dedication to innovation in regenerative medicine and improving surgical outcomes through the introduction of nanOss Strata [4]. - Xtant Medical operates a nationwide distribution network to make nanOss Strata accessible to surgeons [4]. Company Overview - Xtant Medical Holdings, Inc. focuses on the design, development, and commercialization of orthobiologics for chronic and surgical wound care, sports medicine, and spinal implant systems [5].

Core Insights - Xtant Medical Holdings, Inc. has completed the sale of certain non-core Coflex spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC for approximately $19.2 million, which includes $11.0 million in cash and $8.2 million in short-term seller financing [2][3] Financial Details - The transaction's purchase price consists of $11.0 million in cash and $8.2 million in an unsecured promissory note, which is subject to purchase price adjustments and matures on January 15, 2026 [2] - The net proceeds from the sale will be used to reduce long-term debt and enhance cash liquidity for the company [2] Strategic Focus - The sale is viewed as a significant step for Xtant Medical to enhance its focus on its core biologics business, aiming to drive innovation and improve financial performance [3] - The company expects that the net proceeds, along with anticipated cash flows from operations, will allow it to operate without needing additional external capital [3] Company Overview - Xtant Medical is a global medical technology company dedicated to surgical solutions for spinal and orthopedic conditions, with a mission centered on honoring the gift of donation to improve patients' lives [4]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $33.3 million, a 19% increase from $27.9 million in Q3 2024, primarily driven by $5.5 million in licensing revenue [13][14] - Gross margin improved to 66.1% in Q3 2025 from 58.4% in Q3 2024, attributed to a favorable sales mix and greater scale [14] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5 million in the same period last year [16] Business Line Data and Key Metrics Changes - The biologics product family, the core business, grew 4% year-over-year, which was below long-term growth expectations [8][9] - Hardware product revenue declined by 6% or $736,000 year-over-year [13] Market Data and Key Metrics Changes - The company anticipates closing the sale of non-core assets for $19.2 million, which will enhance focus on core biologics and strengthen financial position [5][6] - The sale is expected to be neutral to slightly positive for margins and bottom line metrics in 2026 and beyond [7] Company Strategy and Development Direction - The company is focusing on self-sustainability and positive cash flows, with strategic initiatives aimed at higher margin biologics and in-house manufacturing [9] - Investments are being made in the commercial team to maximize the reach of the orthobiologics portfolio [9][10] - New product launches include CollagenX, which is designed for surgical wound closure and complements the existing product line [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving low double-digit growth in the orthobiologics business for 2026, despite not providing full guidance yet [23][24] - The company is optimistic about the impact of new products and the potential for growth in the surgical repair and wound care markets [11][40] Other Important Information - The company has $10.6 million in cash and equivalents, with $25.6 million in net accounts receivable and $40.7 million in inventory as of September 30, 2025 [17] - The anticipated proceeds from the sale of assets will not require additional external capital for operations [5][6] Q&A Session Summary Question: Plans for investment in the commercial organization - Management indicated plans to increase the number of sales representatives from four to eight by the end of the year, with further additions expected in 2026 [22] Question: Growth expectations for the orthobiologics business - Management expects low double-digit growth in orthobiologics for 2026, with ongoing efforts to optimize the product portfolio [23][24] Question: Insights on new product launches at NAS - Management highlighted three key products: a new growth factor product, an advanced DBM called Trivium, and the recently launched CollagenX [24][25] Question: Year-over-year growth in orthobiologics - The 4% growth was supported by the stem cell and amnio product lines, while older demineralized bone products faced declines [30][31] Question: Impact of amnio product pricing changes - The company is well-positioned to benefit from the new pricing structure in the amnio market due to its low production costs [36][38] Question: Plans for distributing CollagenX - Management sees significant potential for CollagenX in various surgical procedures and is excited about its market opportunities [40]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $33.3 million, a 19% increase from $27.9 million in Q3 2024, primarily driven by $5.5 million in licensing revenue [13][14] - Gross margin improved to 66.1% in Q3 2025 from 58.4% in Q3 2024, attributed to a favorable sales mix and greater scale [14] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5 million in the same period last year [16] Business Line Data and Key Metrics Changes - The biologics product family, the core business, grew 4% year-over-year, which was below long-term growth expectations [8][9] - Hardware product revenue declined by 6% or $736,000 year-over-year [13] Market Data and Key Metrics Changes - The company anticipates closing the sale of non-core assets for $19.2 million, which will enhance focus on core biologics and strengthen financial position [5][6] - The anticipated revenue from the sold business was approximately $23.5 million, which was modestly unprofitable on a standalone basis [7] Company Strategy and Development Direction - The company is focusing on self-sustainability and positive cash flows, with strategic initiatives aimed at higher margin biologics and in-house manufacturing [9] - Investments are being made in the commercial team to maximize the reach of the orthobiologics portfolio [9][10] - New product launches include CollagenX, which is expected to complement existing offerings and address diverse surgical needs [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving low double-digit growth in the orthobiologics business for 2026, despite not providing specific guidance yet [23][24] - The company is optimistic about the impact of new products and the potential for growth in the surgical repair and wound care markets [11][40] Other Important Information - The company has reiterated its 2025 revenue guidance of $131 million to $135 million, reflecting an 11%-15% growth over 2024 [12] - Cash balance as of September 30, 2025, was $10.6 million, with net accounts receivable at $25.6 million and inventory at $40.7 million [17] Q&A Session Summary Question: Plans for commercial organization investments - Management indicated plans to increase the number of sales representatives from four to eight by the end of the year, with further additions expected in 2026 [22] Question: Growth expectations for orthobiologics business - Management expects low double-digit growth in orthobiologics for 2026, with ongoing efforts to optimize the product portfolio [23][24] Question: Highlights for upcoming NAS event - Management highlighted new products such as a growth factor product, advanced DBM called Trivium, and CollagenX as key offerings to showcase [25] Question: Year-over-year growth in orthobiologics - Management noted a 4% growth in orthobiologics, driven by stem cell and amnio product lines, while older demineralized bone products faced challenges [30][31] Question: Impact of amnio product pricing changes - Management expressed confidence in leveraging robust hospital contracts to capitalize on new pricing structures in the amnio market [36][38] Question: Plans for CollagenX distribution - Management sees significant potential for CollagenX in various markets, leveraging existing platforms and FDA work for future growth [40]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $33.3 million, a 19% increase from $27.9 million in Q3 2024, primarily driven by $5.5 million in licensing revenue and $576,000 in additional biologics revenue, despite a 6% decline in hardware product revenue [13][8][4] - Gross margin improved to 66.1% in Q3 2025 from 58.4% in Q3 2024, attributed to a favorable sales mix and greater scale [13] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5 million in the same period last year [16] - Adjusted EBITDA for Q3 2025 was $4.5 million, a significant improvement from an adjusted EBITDA loss of approximately $1 million in Q3 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family, the core business, grew by 4% year-over-year, which was below long-term growth expectations [8] - The company is focusing on higher-margin biologics and in-house manufacturing to improve quality and control costs, with plans to drive top-line growth in the orthobiologics business [9] Market Data and Key Metrics Changes - The company anticipates closing the sale of non-core assets for $19.2 million, which will enhance focus on the core biologics business and strengthen financial position [5][6] - The anticipated revenue from the sold business was approximately $23.5 million, which was modestly unprofitable on a standalone basis [6] Company Strategy and Development Direction - The company is shifting focus back to driving top-line growth in orthobiologics after achieving self-sustainability and positive cash flows [9] - New product launches include CollagenX, which is designed for surgical wound closure and complements the existing orthobiologics product line [10] - The company is well-positioned to grow in the surgical repair and wound care markets, supported by positive feedback from surgeons on recent innovations [11] Management's Comments on Operating Environment and Future Outlook - Management reiterated 2025 revenue guidance of $131 million to $135 million, reflecting an 11%-15% growth over 2024 revenue [11][12] - The company expects to provide initial 2026 revenue guidance with Q4 results in March of next year [12] Other Important Information - The company has $10.6 million in cash and cash equivalents, with net accounts receivable of $25.6 million and inventory of $40.7 million as of September 30, 2025 [17] Q&A Session Summary Question: Plans for investment in the commercial organization - Management indicated plans to increase the number of sales representatives from four to eight by the end of the year, with expectations to add four more in 2026, focusing on strategic areas [19][21] Question: Growth expectations for the orthobiologics business in 2026 - Management expects low double-digit growth for the orthobiologics business in 2026, while hardware growth remains uncertain [22] Question: Insights on new product launches at NAS - Management highlighted three key products: a new growth factor product, an advanced DBM called Trivium, and the recently launched CollagenX, all of which are expected to enhance the product portfolio [25][26] Question: Year-over-year growth in orthobiologics - The orthobiologics business experienced a 4% growth, driven by the stem cell and amnio product lines, while older demineralized bone products faced declines [30][33] Question: Impact of amnio product pricing changes - The company is well-positioned to benefit from the new pricing structure for amnio products, leveraging strong hospital contracts [38] Question: Plans for distributing CollagenX - Management sees significant potential for CollagenX in various markets, leveraging the existing platform technology acquired through previous acquisitions [40][41]

Core Insights - Xtant Medical Holdings, Inc. reported an earnings per share (EPS) of -$0.005, matching estimates, with revenue of approximately $33.26 million, exceeding expectations of $32.70 million [1][6] Financial Performance - The company achieved a total revenue of $33.26 million in the third quarter of 2025, reflecting a 19% increase compared to the previous year [2][6] - XTNT's full-year 2025 revenue guidance remains between $131 million and $135 million, indicating an anticipated growth of 11% to 15% over fiscal year 2024 [3][6] - Despite a negative price-to-earnings (P/E) ratio of -23.14, the price-to-sales ratio stands at 0.78, suggesting the stock is valued at less than one times its sales [2] Strategic Initiatives - The company announced the sale of certain hardware assets and its OUS businesses to Companion Spine, expected to close by the end of the year, which may enhance focus on core operations and improve financial performance [3][6] - Sean Browne, President and CEO, emphasized the company's commitment to self-sustainability through positive free cash flow, as reflected in the strong third-quarter results [4] Liquidity and Debt Position - XTNT maintains a strong liquidity position with a current ratio of 2.47, indicating more than twice the current assets compared to current liabilities [5] - The debt-to-equity ratio is 0.31, suggesting a moderate level of debt relative to equity [5]

Financial Performance - Total revenue for Q3 2025 was $33.3 million, representing a 19% increase year-over-year from $27.9 million in Q3 2024[6] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5.0 million in Q3 2024[8] - Adjusted EBITDA for Q3 2025 was $4.5 million, a significant improvement from an adjusted EBITDA loss of $1.0 million in Q3 2024[9] - Total revenue for the three months ended September 30, 2025, was $33.255 million, an increase from $27.937 million in the same period of 2024, representing a growth of 19.1%[23] - Product revenue for the nine months ended September 30, 2025, reached $87.492 million, compared to $85.754 million in 2024, showing a growth of 2.0%[23] - Net income for the nine months ended September 30, 2025, was $4.916 million, a significant recovery from a net loss of $13.284 million in the same period of 2024[25] - Non-GAAP Adjusted EBITDA for the nine months ended September 30, 2025, was $14.482 million, compared to a loss of $2.488 million in 2024[27] Cost Management - Gross margin improved to 66.1% in Q3 2025, up from 58.4% in the same period last year[7] - Operating expenses decreased to $19.5 million in Q3 2025, down from $20.1 million in Q3 2024[8] - Operating expenses decreased to $19.451 million for the three months ended September 30, 2025, from $20.084 million in 2024, a reduction of 3.2%[23] - The company experienced a significant reduction in loss from operations, reporting a loss of $2.541 million for the three months ended September 30, 2025, compared to a loss of $3.777 million in 2024[23] - Interest expense for the nine months ended September 30, 2025, was $2.953 million, a slight decrease from $3.026 million in 2024[27] Cash Flow and Liquidity - Cash generated from operations was $4.6 million in Q3 2025, compared to cash used in operations of $1.7 million in the prior year quarter[5] - As of September 30, 2025, cash and cash equivalents increased to $10.6 million from $6.2 million at the end of 2024[11] - Cash and cash equivalents at the end of the nine months ended September 30, 2025, totaled $10.641 million, up from $7.086 million in 2024[25] - The company reported a net cash provided by operating activities of $7.166 million for the nine months ended September 30, 2025, compared to a net cash used of $12.561 million in 2024[25] Strategic Initiatives - The company reiterated its full-year 2025 revenue guidance of $131-$135 million, indicating growth of 11%-15% over FY24[12] - The anticipated sale of non-core assets and international businesses to Companion Spine is expected to close by year-end 2025[5] - The company launched CollagenX™, a new bovine collagen particulate product aimed at enhancing surgical wound closure[5]